• Minoli A Perera, Larisa H Cavallari, Nita A Limdi, Eric R Gamazon, Anuar Konkashbaev, Roxana Daneshjou, Anna Pluzhnikov, Dana C Crawford, Jelai Wang, Nianjun Liu, Nicholas Tatonetti, Stephane Bourgeois, Harumi Takahashi, Yukiko Bradford, Benjamin M Burkley, Robert J Desnick, Jonathan L Halperin, Sherief I Khalifa, Taimour Y Langaee, Steven A Lubitz, Edith A Nutescu, Matthew Oetjens, Mohamed H Shahin, Shitalben R Patel, Hersh Sagreiya, Matthew Tector, Karen E Weck, Mark J Rieder, Stuart A Scott, Alan H B Wu, James K Burmester, Mia Wadelius, Panos Deloukas, Michael J Wagner, Taisei Mushiroda, Michiaki Kubo, Dan M Roden, Nancy J Cox, Russ B Altman, Teri E Klein, Yusuke Nakamura, and Julie A Johnson.
• Section of Genetic Medicine, Department of Medicine, University of Chicago, IL, USA.
• Lancet. 2013 Aug 31; 382 (9894): 790796790-6.

BackgroundVKORC1 and CYP2C9 are important contributors to warfarin dose variability, but explain less variability for individuals of African descent than for those of European or Asian descent. We aimed to identify additional variants contributing to warfarin dose requirements in African Americans.MethodsWe did a genome-wide association study of discovery and replication cohorts. Samples from African-American adults (aged ≥18 years) who were taking a stable maintenance dose of warfarin were obtained at International Warfarin Pharmacogenetics Consortium (IWPC) sites and the University of Alabama at Birmingham (Birmingham, AL, USA). Patients enrolled at IWPC sites but who were not used for discovery made up the independent replication cohort. All participants were genotyped. We did a stepwise conditional analysis, conditioning first for VKORC1 -1639G→A, followed by the composite genotype of CYP2C9*2 and CYP2C9*3. We prespecified a genome-wide significance threshold of p<5×10(-8) in the discovery cohort and p<0·0038 in the replication cohort.FindingsThe discovery cohort contained 533 participants and the replication cohort 432 participants. After the prespecified conditioning in the discovery cohort, we identified an association between a novel single nucleotide polymorphism in the CYP2C cluster on chromosome 10 (rs12777823) and warfarin dose requirement that reached genome-wide significance (p=1·51×10(-8)). This association was confirmed in the replication cohort (p=5·04×10(-5)); analysis of the two cohorts together produced a p value of 4·5×10(-12). Individuals heterozygous for the rs12777823 A allele need a dose reduction of 6·92 mg/week and those homozygous 9·34 mg/week. Regression analysis showed that the inclusion of rs12777823 significantly improves warfarin dose variability explained by the IWPC dosing algorithm (21% relative improvement).InterpretationA novel CYP2C single nucleotide polymorphism exerts a clinically relevant effect on warfarin dose in African Americans, independent of CYP2C9*2 and CYP2C9*3. Incorporation of this variant into pharmacogenetic dosing algorithms could improve warfarin dose prediction in this population.FundingNational Institutes of Health, American Heart Association, Howard Hughes Medical Institute, Wisconsin Network for Health Research, and the Wellcome Trust.Copyright © 2013 Elsevier Ltd. All rights reserved.

23 keywords...

hide…